Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Farletuzumab (Primary) ; Carboplatin; Doxorubicin liposomal; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd; Morphotek
- 07 Feb 2023 Primary endpoint has not been met, (Progression Free Survival (PFS), as per Results published in the Gynecologic Oncology
- 07 Feb 2023 Results published in the Gynecologic Oncology
- 26 Oct 2020 This trial has been Completed in Belgium (Global End Date: 13 Aug 2020), according to European Clinical Trials Database record.